AI-enabled real world evidence for rare diseases

Bringing the power of artificial intelligence, longitudinal clinical data and genomics to rare disease discovery, development and commercialization

Longitudinal clinical and administrative data enriched with genomics and supported by AI-based predictive analytics

Discover our Products

Improving outcomes for patients living with rare diseases

About Triaxia

Powering the discovery, development, and deployment of new rare disease therapies

Our combined longitudinal clinical and administrative data, enriched with genomics and enabled by AI, delivers against the complete range of biopharma RWE needs

Our team combines experienced healthcare informatics professionals with expert clinicians from leading AMCs

About Us

TriAxia’s mission is to improve outcomes for patients living with rare diseases

We combine proprietary Clinical, Genomic, and Administrative data to enable to Discovery, Development, and Commercialization of rare-disease therapies

Team & Advisors

Our team.

Tanya Moreno, PhD

Raymond Benza, MD

Franz Rischard, DO

Evelyn Horn, MD

Michael Risbano, MD

Aaron Waxman, MD, PhD

Roham Zamanian, MD

Robert Epstein, MD

Jonathan White, MD

J. Marc Overhage MD, PhD

Tanya Moreno, PhD

Raymond Benza, MD

Franz Rischard, DO

Evelyn Horn, MD

Michael Risbano, MD

Aaron Waxman, MD, PhD

Roham Zamanian, MD

Robert Epstein, MD

Jonathan White, MD

J. Marc Overhage MD, PhD

Examples of the impact our products have had for our clients

From use of our genomic data to validate a novel target for an early stage biotech to large scale retrospective clinical studies in support of multi-billion dollar drugs for top global pharmas, TriAxia provides the rare disease clinico-genomic data our clients need

The model correctly predicted COPD-PH in 93.5% of patients analyzed

RWE + Advanced Analytics

Global biopharma algorithm to detect COPD-PH patients

To enable recruitment for a Phase III trial, we developed an algorithm to detect undiagnosed patients with COPD-PH from generally available clinical data

of US Patients achieved MCI

Clinical Trial Support

Global biopharma study of ‘Multi-Clinical Improvement’ (MCI) in US PAH patients as comparator to phase III Clinical Trial results

A top 5 global pharma needed data to support the Phase III trial of their latest blockbuster

relevant genes differentially expressed in cases vs controls

Bioinformatics & Genomics

Role of target pathway in disease pathophysiology for pre-clinical molecule

An early stage biotech had animal model data for a novel target and wanted to confirm with in-human genomics

TriAxia publications can be found in the leading colleges, conferences and journals in healthcare

Our most recent publications at ATS, CHEST and elsewhere showcase our current work in rare pulmonary diseases

View All Publications